Kornimate/medical-research-clean huggingface dataset:
assessment of biomarkers for recurrent hcv infection post-liver transplantation

Conditions: Hepatitis C Virus

Summary: the purpose of this study is to learn about how different immunosuppressant therapies impact on recurrent hepatitis c virus infection in the new liver after liver transplant. we will be evaluating if cyclosporin a has a superior effect against recurrent hepatitis c virus (hcv) infection than tacrolimus.

we will address the hypothesis that csa has a superior antiviral effect against hcv than tacrolimus by assessing serial hcv rna levels in serum. we plan to address the hypothesis that csa is more efficient in limiting viremia than tacrolimus and that viremia is predictive of long-term clinical outcome of hepatic fibrosis that is known to impact on both graft and patient survival

Eligibility criteria:
inclusion criteria: * about to undergo a primary liver transplant (including living donor, split liver) and are hcv positive. * willing and capable of giving written consent for study participation * expected to be capable of study participation for full 24 months post-transplantation. * allograft biopsies will be possible * expected use of calcineurin inhibitor (neoral or tacrolimus) as primary immunosuppression an immunosuppressive regimen consisting of a calcineurin inhibitor (neoral or tacrolimus) in combination with simulect and mycophenolate sodium exclusion criteria: * this is a multi-organ transplant or if the patient has previously been transplanted with any other organ. * this is a liver transplant from a non-heart beating donor. * this is an abo incompatible transplant. * patients with serum creatinine level \> 250 umol/l. * the recipient is seropositive for human immunodeficiency virus (hiv) antibodies. * fulminant liver failure is the reason for transplant. * patient is participating in other clinical trial involving exploratory drug * there is a known malignancy, or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin, or hepatocellular carcinoma less than 5 cm meeting milan criteria for transplantation5. * the patient is being transplanted for hepatic malignancy with greater than 5 known lesions. * severe coexisting disease is present or if any unstable medical condition is present which could affect the study objectives. * a female transplant candidate is pregnant, lactating or of childbearing potential and not practicing an acceptable method of contraception. * an unlicensed drug or therapy has been administered within one month prior to study entry or if such therapy is to be instituted post-transplantation.

Keywords: hepatitis c virus hcv liver transplant cyclosporine tacrolimus myfortic
respiratory function and walking capacity in multiple sclerosis

Conditions: Multiple Sclerosis; Respiratory; Disorder, Functional, Impaired; Difficulty Walking

Summary: multiple sclerosis (ms) is a chronic progressive neurological disease. respiratory dysfunction due to weakness in the respiratory musculature has been described in ms. this leads to increased morbidity and mortality in late stages of the disease. it is possible that respiratory dysfunction influence physical fitness in earlier stages as well. walking disability and fatigue causes significant impact on health in patients with ms, even in earlier stages. the hypothesis is that there is a relationship between respiratory function, walking capacity and fatigue and that daily deep breathing exercise during two months will improve respiratory function, walking capacity and fatigue.

presented above.

Eligibility criteria:
inclusion criteria: * inhabitant in orebro county, sweden, that are diagnosed with ms according to the revised mcdonald criteria and registered in the swedish ms-registry with edss (expanded disability status scale) score in the interval ≥ 3.0 - ≤ 7.0. * participants must understand verbal and written information and must be relapse free ≥ 3 months prior to inclusion. exclusion criteria: * patients with diseases that may have influence on walking ability and respiratory function (other than ms). such conditions include heart and lung diseases, orthopedic disorders, patients recently subjected to surgery, and non-ms related neurological dysfunction.

Keywords: multiple sclerosis self-assessment physical endurance respiratory function fatigue
cognitive behavioral therapy for the prevention of paranoia in adolescents at high risk

Conditions: ARMS; APS; Prodromal Symptoms

Summary: the main objective of this study is to decrease the severity of symptoms and improve psycho-social functioning in youth at high risk of developing psychosis by providing a specialized group-and-family-based cognitive behavioral therapy (gf-cbt).

24 adolescents and young adults between the ages of 12 and 25 who are at high risk of developing psychosis and exhibit paranoid ideation will be recruited to participate in a pilot randomized controlled trial. subjects will be randomly assigned to the intervention (gf-cbt)or control (symptom monitoring) groups. gf-cbt is based on a cognitive neuropsychiatric model of delusions, and incorporates recent developments in learning and cognitive theories. gf-cbt consists of individual, group, and family group sessions. the three-part program teaches adolescents and family members cognitive behavioral skills that they can continue using on their own after completion of the program. preliminary efficacy of the intervention will be evaluated using standardized measures by blind evaluators conducted at baseline, post-treatment, and post-termination follow-up over the next 2 years. hypotheses: (a) gf-cbt will be associated with: high rate of remission from "at risk status" and low rates of transition to psychosis (defined by caarms criteria); greater improvements in severity of symptoms; and improved functioning; (b) decrease in family members'level of stress, and improved coping; (c) family members will demonstrate proficiency in cbt skills.

Eligibility criteria:
inclusion criteria: * meets criteria for arms (at risk mental state, assessed by caarms) * elevated suspiciousness (panss,p6≥3) exclusion criteria: a diagnosis of any of the following: * moderate to severe learning disability * substance dependence * organic impairment known to affect brain

Keywords: at risk mental state attenuated psychosis syndrome prodrom paranoia psychosis cognitive behavioral therapy group family arms
comparison of topical minoxidil 5% in ethanol plus propylene glycol versus minoxidil 5% in ethanol alone in treatment of women with female pattern hair loss

Conditions: Female Pattern Hair Loss

Summary: the study will be included 60 women with fphl. the diagnosis of fphl will be established by clinical (ludwig classification) and trichoscopic evaluation of frontal and occipital regions of the scalp.

enrolled women will be randomly assigned into 3 treatment groups: group a will apply topical minoxidil 5% in 90% ethanol and 5% propylene glycol, group b will apply topical minoxidil 5% in pure ethanol alone and group c will apply pure ethanol (placebo) twice daily. the treatment will be continued for six months with regular visits at 3 months intervals. the medications will be provided in bottles which were identical in shape and color, and were coded by a third party. both patients and investigator will be blinded to the medication. disclosure of the codes will be done, by a third party, at the end of the study.

Eligibility criteria:
inclusion criteria: * fphl exclusion criteria: * no

Keywords: female pattern hair loss minoxidil.
study of efficacy and safety of erenumab in adult chronic migraine patients

Conditions: Migraine

Summary: the purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in asian population.

this study used a single-cohort, 2-treatment arms, randomized (1:1 (70 mg:placebo)), double-blind study design in adult subjects with chronic migraine. a screening period of 2 weeks was used to assess initial eligibility, followed by a 4-week baseline period to assess diary compliance and headache frequency. eligible patients were then randomized to either erenumab 70 mg or placebo for 12 weeks, followed by an open-label treatment period to last until end of pta determined by the product launch in the country or the country's decision not to launch. a safety follow-up visit occurred 12 weeks after the last treatment for subjects who discontinue the double-blind treatment or who completed the double-blind treatment period without continuing in the open-label treatment period.

Eligibility criteria:
key inclusion criteria: 1. history of at least 5 attacks of migraine 2. ≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period 3. \>=80% diary compliance during the baseline period key exclusion criteria: 1. older than 50 years of age at migraine onset 2. history of cluster or hemiplegic headache 3. evidence of seizure or major psychiatric disorder 4. cardiac or active hepatic disease 5. pregnant or nursing

Keywords: amg334 erenumab migraine chronic headache chinese
silver nanoparticle investigation for treating chronic sinusitis

Conditions: Chronic Rhinosinusitis (Diagnosis)

Summary: chronic rhinosinusitis is a highly prevalent disease resulting in high economic burden. effective therapeutic options are needed. rhinosinusitis-related biofilms are a likely contributor to recalcitrant disease. emerging evidence shows that colloidal silver nanoparticles may be effective for reducing biofilms. the investigators intend to perform a randomized, double-blinded, placebo-controlled clinical trial to evaluate the effectiveness and safety of intranasal colloidal silver nanoparticles in adult patients with chronic rhinosinusitis. the investigators hypothesize that compared to placebo, treatment with intranasal colloidal silver for chronic rhinosinusitis will lead to a significant improvement in symptom scores and will not be associated with increased rate of adverse effects.


Eligibility criteria:
inclusion criteria: twelve (12) weeks or longer of two or more of the following signs and symptom consistent with chronic rhinosinusitis (crs): * mucopurulent drainage (anterior, posterior, or both), nasal obstruction (congestion), facial pain-pressure-fullness, or decreased sense of smell and inflammation is documented by one or more of the following findings: * purulent (not clear) mucus or edema in the middle meatus or ethmoid region * polyps in nasal cavity or the middle meatus * and/or radiographic imaging showing inflammation of the paranasal sinuses exclusion criteria: * unable to speak english * history of nasal or sinus surgery within past 6 weeks * history of comorbid ciliary dyskinesia, cystic fibrosis or any other mucociliary condition * dependence on prolonged corticosteroid therapy for comorbid condition * history of renal impairment * history of cerebrospinal fluid leak
robotic-assisted training after upper arm fracture

Conditions: Shoulder Injury

Summary: in this study, patients with upper arm fracture will receive an additive robotic-assisted training using the armeo®spring robot for three weeks on the injured arm in addition to conventional physio- and occupational therapy. the supportive treatment and execution of specific exercises on the armeo®spring should lead to improved recovery of function and mobility of the upper arm compared to conservatively treated patients.

60 patients aged between 35 and 70 years with proximal humeral fracture and surgical treatment will be recruited in three different clinics in germany and randomised into an intervention and a control group. participants will be assessed before randomisation and followed up after completing an intervention period of 3 weeks and additionally after 3, 6 and 12 months. baseline assessment will assess cognition (somc), level of pain in the affected arm, ability to work, gait speed (10m walk), disability of the arm, shoulder and hand (dash), as well as the range of motion of the affected arm (goniometer measurement), visual acuity and motor function of orthopaedic patients (wmft-o). clinical follow up directly after intervention will assess disability of the arm, shoulder and hand (dash), the range of motion and motor function (wmft-o). primary outcome parameter will be the dash and secondary outcome parameter will be the wmft-o. the long-term results will be assessed prospectively by a postal follow-up. all patients will receive conventional occupational- and physiotherapy. the intervention group will receive an additive robotic-assisted training using the armeo®spring robot for three weeks.

Eligibility criteria:
inclusion criteria: * surgical treatment of the shoulder joint after upper arm fracture classified as type ao 11 * movement-stable fracture * inclusion between the fourth and the seventh week after surgery exclusion criteria: * limited cognition as defined by a score in short-orientation-memory-concentration test (somc) less than 10 points * inadequate level of pain during movement of the affected shoulder joint (pain score \>5 on a visual analogue pain scale) * strongly limited vision or hearing * heart failure (new york heart association stage iii-iv) or copd (chronic obstructive pulmonary disease) gold stage iii-iv * walking speed \<0.8m/sec * isolated tuberculum majus fracture of the humerus (ao 11, a1) * fractures with involvement of the glenoid cavity * double fractures * injury of the plexus or the axillaris nerve

Keywords: robotic-assisted rehabilitation humeral fracture randomised controlled study
neuro-psychosocial teleassistance for neuromuscular diseases

Conditions: Social Competence; Self Esteem; Quality of Life; Social Skills; Neuromuscular Diseases

Summary: this is a clinical trial to assess the effect of a neuropsychosocial intervention by means of telecare aimed at children and adolescents aged 7-16 years with neuromuscular diseases. the intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. the intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.

development of a neuro-psychosocial tele-assistance programme for groups of children and adolescents affected by various neuromuscular diseases, including duchenne/becker muscular dystrophy, limb-girdle dystrophy, etc. in this project the variables of interest and intervention include social cognition, quality of life, psychological symptomatology and coping strategies. the aim of this study is to test whether this programme improves the indicators in the mentioned variables.

Eligibility criteria:
inclusion criteria: * to be diagnosed with a neuromuscular disease by a specialist * being between 7 and 16 years old * having signed an informed consent form through their legal guardians prior to participation in the study * having spanish as one of their main languages * having access to a computer (with a camera, microphone and speakers integrated) and internet connection to take part in the videoconferences exclusion criteria: * presence of any other diagnosis or sensory deficit that would prevent the application of the tests or hinder the correct performance of the intervention´s activities * being illiterate
memantine in bipolar patients with alcoholism

Conditions: AOD Effects and Consequences

Summary: since memantine may not only inhibit overactivity of microglial cell, but also repair the damaged neurons and neurogenesis through activation of astroglial cell and release of neurotrophic factors, the investigators propose that the neurotrophic effect of memantine may benefit neurodegenerative diseases including bipolar disorders (bp) and alcohol dependence. in the current study, the investigator will investigate whether add-on memantine at a dose of 5 mg/day has a beneficial effect on bp comorbid with alcohol dependence.

each individual enter into this project will receive regulate treatment adding-on memantine medication. during each visit, patients will receive evaluation for their symptoms and plasma brain-derived neurotropic factor (bdnf), cytokines (e.g.., interleukin-6(il-6), il-8) and neuropsychological performance.

Eligibility criteria:
inclusion criteria: 1. male or female patient aged ≧18 and ≦65 years. 2. signed informed consent by patient or legal representative. 3. the chinese version of the modified structural interview of affective disorder and schizophrenia-l(sads-l), a semi-structured interview aimed at formulating the main bipolar ii diagnoses based upon dsm-iv-tr criteria 4. a 2-day minimum for hypomania to diagnose bp. 5. patient or a reliable caregiver was expected to ensure acceptable compliance and visit attendance for the duration of the study. exclusion criteria: 1. females who are pregnant or nursing. 2. women of childbearing potential not using adequate contraception as per investigator judgment or not willing to comply with contraception for duration of study. 3. patient has received memantine, other anti-inflammatory medication within 1 week prior to first dose of double-blind medication, such as cyclo-oxygenase 2 (cox-2) inhibitors. 4. clinically significant medical condition e.g., cardiac, hepatic and renal disease with current evidence of poor controlled. 5. patient has received electroconvulsive therapy (ect) within 4 weeks prior to the first dose of double-blind medication. 6. increase in total sgot, sgpt, bun and creatinine by more than 3x upper limit of normal.
clinical performance of the oxyaqua daily disposable silicone hydrogel soft contact lens

Conditions: Myopia

Summary: the objective of this study is to demonstrate that the oxyaqua silicone hydrogel soft contact lens could be prescribed as a supportive care for myopes.

this is a double blind randomized control study to evaluate a daily disposable contact lens. it is planned to have 30 evaluable subjects at least divided evenly among 3 independent pis from one hospital. each pi will enroll 12 subjects at least. the ration of evaluable test subjects to control subjects will be 2 to 1. the study lens will be dispensed randomly to subjects who have normal ocular health and conform to a set of criteria. it is necessary to wear the lens 8 hours a day and 5 days a week at least and follow up for one month (30 days). data will be collected at baseline, 1 week, 2 week and 4 week of daily disposable modality including adverse reactions, slit-lamp findings and symptoms, problems, and complaints, vision acuity, keratometry change and reason for discontinuation.

Eligibility criteria:
inclusion criteria: * subjects should have normal eyes and use no ocular medications. they may have worn contact lenses previously, provided their eyes are shown to be normal at the start of the investigation. a normal eye is defined as having the following characteristics: 1. no anterior segment infection, inflammation or abnormality. 2. no other active ocular or systemic disease that would contraindicate contact lens wear; and 3. no medications that would contraindicate contact lens wear. * va correctable to 0.1 logmar or better, with spherical lenses ranging in power from * 1.00 to -10.00 d myopia, astigmatism less than 2.00 d * willing to comply with all study procedures and be available for the duration of the study. * provide signed and dated informed consent form. exclusion criteria: * have history of allergies that would contraindicate "normal" contact lens wear. * have other active ocular or systemic disease such as, but not limited to: anterior uveitis (past or present), glaucoma, sjögren's syndrome, lupus erythematosus, sclerodermas, keratoconus or type ii diabetes, slip lamp findings greater than grade i (such as cornea or interstitial edema). * have medications that would contraindicate contact lens wear. * have had any cornea surgery. * currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next 1 month. * any active participation in another clinical trial within 30 days prior to this study. * the presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. * a known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections. * a history of papillary conjunctivitis that has interfered with contact lens wear. * no monocular or monovision fits. * alcoholic or drug abused.

Keywords: silicone hydrogel soft contact lens
senescent endometrial cells in patients with thin endometrial lining

Conditions: Asherman's Syndrome; Thin Endometrial Lining; Cell Senescence

Summary: the goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives. the main question it aims to answer is: are there any senescent cells present in thin endometrial lining? during the luteal phase of the cycle, participants will will undergo: * gynecologic us to measure the endometrial lining thickness and pattern. * endometrial biopsy with pipelle catheter

the investigators hypothesized that senescent cells in the endometrium may be the cause of the failure of thin endometrium to respond to normal growth stimuli such as estrogen. the outcome that research team anticipate to measure is the percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies.

Eligibility criteria:
inclusion criteria: * age 18-39 * bmi - up to 35 * thin endometrium after ocp use * asherman's syndrome * women already undergoing endometrial biopsy for infertility testing (eg. emma testing) * women with archived endometrial biopsy samples exclusion criteria: * women with systemic disease (rheumatic disease, dm) * women with coagulopathies * women with active pelvic inflammatory process * uterine anomalies * pregnant women * any hormonal contraception use or iud